TABLE 3.

Treatments for Covid-19 in solid organ transplant recipients hospitalized for Covid-19 during early and late 2020

Treatment, n (%)	Early period (n = 571)	Late period (n = 402)	p-valuea
Corticosteroidsa	62 (10.9)	243 (61.4)	<.001*
Remdesivir	50 (8.8)	213 (53.0)	<.001*
Anti-IL−6/IL−6R agents	73 (12.8)	5 (1.2)	<.001*
Hydroxychloroquine	329 (60.0)	4 (1.0)	<.001*
Convalescent plasma	48 (8.4)	119 (29.6)	<.001*
Monoclonal antibodies targeting SARS-CoV−2	0 (0.0)	3 (0.8)	.07
Any decrease in maintenance of immunosuppressionb	322 (79.1)	265 (65.9)	.05*
Hold antimetabolitec	270 (66.5)	206 (65.8)	.87
Decrease antimetabolitec	51 (12.6)	31 (9.9)	.27
Decrease CNI trough goaldef	160 (30.3)	49 (13.3)	<.001*

Abbreviations: CNI, calcineurin inhibitor; CI, confidence interval; IL-6R, interleukin-6 (IL-6), interleukin-6 receptor; OR, odds ratio.

^ap-values reflect χ² and Fisher’s exact tests for heterogeneity. *Indicates statistical significance at α = .05.

^bDosed at ≥6 mg dexamethasone equivalents per day.

^cComplete cessation or reduction in the dose or goal trough of at least one maintenance immunosuppressive agent. Some patients had more than one change. In the early period, corticosteroids were stopped in 2/438 (0.5%) patients taking steroids at baseline. In the late periods, steroids were stopped in 1/277 (0.3%) and decreased in 1/277 (0.3%) patients taking steroids at baseline.

^dRefers to percentage of patients taking and antimetabolite at the time of Covid-19 diagnosis (406 patients in the early period and 313 patients in the late period).

^eRefers to percentage of patients taking a calcineurin inhibitor at baseline (528 patients in the early period and 368 patients in the late period).

^fRefers to percentage of patients taking a corticosteroid at baseline (438 patients in the early period and 277 patients in the late period). Corticosteroid dose was decreased in one patient in the late period; all other steroid decrease involved complete cessation.